Literature DB >> 31980565

Impacts of genomics on the health and social costs of intellectual disability.

Brett Doble1,2, Deborah Schofield3,4, Carey-Anne Evans5, Tudor Groza6, John S Mattick3,7, Mike Field8, Tony Roscioli5,9.   

Abstract

BACKGROUND: This study provides an integrated assessment of the economic and social impacts of genomic sequencing for the detection of monogenic disorders resulting in intellectual disability (ID).
METHODS: Multiple knowledge bases were cross-referenced and analysed to compile a reference list of monogenic disorders associated with ID. Multiple literature searches were used to quantify the health and social costs for the care of people with ID. Health and social expenditures and the current cost of whole-exome sequencing and whole-genome sequencing were quantified in relation to the more common causes of ID and their impact on lifespan.
RESULTS: On average, individuals with ID incur annual costs in terms of health costs, disability support, lost income and other social costs of US$172 000, accumulating to many millions of dollars over a lifetime.
CONCLUSION: The diagnosis of monogenic disorders through genomic testing provides the opportunity to improve the diagnosis and management, and to reduce the costs of ID through informed reproductive decisions, reductions in unproductive diagnostic tests and increasingly targeted therapies. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cost analysis; intellectual disability; monogenic disorders; population genomic sequencing; whole-genome sequencing

Mesh:

Year:  2020        PMID: 31980565     DOI: 10.1136/jmedgenet-2019-106445

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  4 in total

1.  Rapid disease progress in a PVOD patient carrying a novel EIF2AK4 mutation: a case report.

Authors:  Xiaofang Zeng; Fan Chen; Anandharajan Rathinasabapathy; Tangzhiming Li; Agila Adnan Ali Mohammed Mohammed; Zaixin Yu
Journal:  BMC Pulm Med       Date:  2020-07-06       Impact factor: 3.317

2.  Paediatric genomic testing: Navigating medicare rebatable genomic testing.

Authors:  Rani Sachdev; Mike Field; Gareth S Baynam; John Beilby; Maria Berarducci; Yemima Berman; Tiffany Boughtwood; Marie B Cusack; Vanessa Fitzgerald; Jeffery Fletcher; Mary-Louise Freckmann; Natalie Grainger; Edwin Kirk; Ben Lundie; Sebastian Lunke; Lesley McGregor; David Mowat; Gayathri Parasivam; Vanessa Tyrell; Mathew Wallis; Susan M White; Alan S L Ma
Journal:  J Paediatr Child Health       Date:  2021-02-10       Impact factor: 1.954

3.  Continuing the sequence? Towards an economic evaluation of whole genome sequencing for the diagnosis of rare diseases in Scotland.

Authors:  Michael Abbott; Lynda McKenzie; Blanca Viridiana Guizar Moran; Sebastian Heidenreich; Rodolfo Hernández; Lynne Hocking-Mennie; Caroline Clark; Joana Gomes; Anne Lampe; David Baty; Ruth McGowan; Zosia Miedzybrodzka; Mandy Ryan
Journal:  J Community Genet       Date:  2021-08-20

4.  Whole exome and genome sequencing in mendelian disorders: a diagnostic and health economic analysis.

Authors:  Marcel E Dinger; Tony Roscioli; Lisa J Ewans; Andre E Minoche; Deborah Schofield; Rupendra Shrestha; Clare Puttick; Ying Zhu; Alexander Drew; Velimir Gayevskiy; George Elakis; Corrina Walsh; Lesley C Adès; Alison Colley; Carolyn Ellaway; Carey-Anne Evans; Mary-Louise Freckmann; Linda Goodwin; Anna Hackett; Benjamin Kamien; Edwin P Kirk; Michelle Lipke; David Mowat; Elizabeth Palmer; Sulekha Rajagopalan; Anne Ronan; Rani Sachdev; William Stevenson; Anne Turner; Meredith Wilson; Lisa Worgan; Marie-Christine Morel-Kopp; Michael Field; Michael F Buckley; Mark J Cowley
Journal:  Eur J Hum Genet       Date:  2022-08-15       Impact factor: 5.351

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.